Search Bar & Filters
Found 24 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating two treatment combinations for patients with BRAF-V600 mutant melanoma that has spread to the brain. This phase II trial compares encorafenib, binimetinib, and nivolumab with ipilimumab and nivolumab to see which is more effective in shrinking and controlling brain metastases from melanoma. The study also aims to assess survival, response rates, duration of response, and toxicity of these treatments. Participants are randomly assigned to one of two groups. One group receives encorafenib once daily by mouth, binimetinib twice daily by mouth, and nivolumab intravenously on the first day of each 28-day cycle. The other group receives nivolumab intravenously on day one of all cycles and ipilimumab intravenously over 30 minutes on day one of the first four 21-day cycles, then nivolumab every 28 days. Treatment continues until disease progression or unacceptable side effects. During the study, participants undergo brain and tumor imaging, physical exams, and laboratory tests. After completing treatment, they are followed every six months for two years and then annually up to three years from randomization. Researchers monitor progression-free survival, overall survival, tumor response, brain metastasis response, and safety. Samples of tissue, cerebrospinal fluid, stool, and blood are collected for future research.
Actively Recruiting
Researchers are evaluating the use of carboplatin chemotherapy given before surgery in patients with high-risk prostate cancer who have inherited mutations in the BRCA1 or BRCA2 genes. This phase II trial aims to determine how well carboplatin works in shrinking tumors prior to surgery and to assess its impact on disease progression and survival. The study also monitors treatment side effects and collects tissue samples for future research. Participants receive carboplatin intravenously before undergoing prostate surgery. Those who show signs of disease progression after surgery will have imaging tests such as CT, MRI, chest X-ray, or PSMA PET scans. Blood samples are collected throughout the trial to monitor health and support additional studies. The study includes detailed follow-up to evaluate treatment outcomes and safety. During the trial, participants will have regular assessments including physical exams, PSA tests, and imaging scans if needed. Researchers will review the rate of complete tumor response after carboplatin treatment at surgery and track progression-free survival and overall survival over time. Safety and side effects of the treatment are closely monitored. Participation may last up to five years with ongoing collection of health data and specimens.
Actively Recruiting
Healthy Volunteer
Researchers are collecting blood and tissue samples from people with and without cancer to help develop and evaluate tests for early cancer detection. This observational study aims to create a blinded reference set of blood samples from cancer and non-cancer patients to validate new blood-based multi-cancer early detection tests. The study also evaluates test performance at the time of initial cancer diagnosis by tumor type and clinical stage. Participants complete a questionnaire at the start of the study and provide blood samples at registration and again 12 months later. Patients diagnosed with cancer may also provide tissue samples at these same times. The study collects these biospecimens to help researchers study and validate early cancer detection assays in the laboratory. During the study, participants are monitored with follow-up at one year after enrollment. Researchers assess the quality and usefulness of the collected blood samples as a blinded reference set for cancer detection tests. The main outcome is the provision of these samples over up to one year, with additional evaluation of test performance by tumor type and stage. Participants involvement includes questionnaires, blood draws, and possible tissue sample collection, with no treatment interventions involved.
Actively Recruiting
Researchers are collecting biological samples and medical data from patients who experience serious side effects after receiving immunotherapy treatments for cancer. This observational study aims to build a national collection of these samples and data to help future research better predict, prevent, and manage these immune-related adverse events, rare infections, or rapid tumor growth. Participants provide tissue, blood, and optionally stool samples if they experience colitis, shortly after confirmation of a severe immune-related side effect and again one month later. Their medical records will be reviewed for up to one year to gather detailed clinical information. This study does not involve administering treatments but focuses on collecting data and samples from those already treated with immuno-oncology therapies. During the study, participants undergo sample collections at registration and one month later. Researchers will review medical records over a year to monitor health outcomes and side effects. The main measurement is establishing the biorepository of samples and data for future studies. Participation duration can last up to one year with periodic assessments based on medical record review and sample collection.
Actively Recruiting
Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.
Actively Recruiting
Researchers are studying colorectal cancer incidence in people aged 45 to 70 who have 1 to 2 small, non-advanced adenomas found on colonoscopy. The trial compares two surveillance strategies performing follow-up colonoscopies at both 5 and 10 years versus only at 10 years. The goal is to better understand the timing and benefit of surveillance colonoscopy for this common condition, as current guidelines vary and lack strong randomized evidence. Participants are randomly assigned to receive either a surveillance colonoscopy at 5 and 10 years or at 10 years only after their qualifying colonoscopy. The colonoscopies will follow current quality guidelines, with all polyps completely removed during the initial exam. Standard preparation instructions will be given before each colonoscopy. This study aims to provide clear evidence on the best interval for surveillance after detecting non-advanced adenomas. During the study, participants will be monitored for colorectal cancer development over 10 years, which is the primary outcome measure. Follow-up includes scheduled colonoscopies and any necessary unscheduled procedures according to clinical need. The study will collect data on cancer incidence to guide future clinical recommendations. Participants will be followed until the study ends with safety and health closely observed throughout their participation.
Actively Recruiting
Researchers are studying how certain factors like age, gender, other medical conditions, and the type of immunotherapy affect whether patients with malignant solid tumors develop mild or serious side effects from immune checkpoint inhibitor treatments. This observational study aims to develop and validate a model that predicts severe immune-related side effects during the first year of immunotherapy, while also assessing quality of life and adverse events over 12 months. The study is sponsored by the SWOG Cancer Research Network and includes translational medicine goals such as evaluating cytokine levels as predictors and establishing a tissue and blood sample repository. Participants will provide a tissue sample at the start of their routine cancer treatment and complete questionnaires at multiple time points at treatment start, and weeks 4, 12, 24, and 52. They may also provide optional blood samples during the study. This design allows researchers to monitor immune-related side effects and patient-reported outcomes over time. During the study, participants will complete various questionnaires to report their quality of life, cognitive function, and side effects. Blood and tissue samples will be analyzed to explore predictive markers of toxicity. Researchers will track the occurrence of severe immune-related side effects over 52 weeks and assess changes in patient-reported outcomes. The study includes ongoing monitoring and data collection, with participation lasting approximately one year from treatment start.
Actively Recruiting
Researchers are evaluating the side effects and effectiveness of adding inotuzumab ozogamicin to frontline chemotherapy for young adults aged 18 to 39 with newly diagnosed B acute lymphoblastic leukemia, a type of blood cancer. Inotuzumab ozogamicin is a targeted therapy that delivers a chemotherapy drug directly to cancer cells. This phase III trial aims to confirm the safety and improve event-free survival compared to standard pediatric-inspired chemotherapy. Participants receive a combination of chemotherapy drugs in several treatment courses, including remission induction, remission consolidation, interim maintenance, delayed intensification, and maintenance therapy. Those in the experimental group receive inotuzumab ozogamicin intravenously on specific days alongside chemotherapy, with additional treatments like blinatumomab given if minimal residual disease is detected. Procedures such as bone marrow biopsies and imaging are performed throughout. Participants will be closely monitored through blood tests, bone marrow samples, imaging scans, and symptom assessments. Researchers will measure outcomes like event-free survival, disease-free survival, overall survival, response rates, and adverse events over several years. After treatment, participants are followed regularly for up to 10 years to assess long-term effects and survival.
Actively Recruiting
Researchers are studying patients with high-risk smoldering multiple myeloma to compare how well lenalidomide and dexamethasone work with or without daratumumab in treating this condition. The trial aims to assess overall survival, progression-free survival, response rates, safety, and quality of life among participants, while also exploring treatment adherence and disease markers over time. Participants are randomly assigned to one of two groups. One group receives daratumumab intravenously on a set schedule along with oral lenalidomide daily and oral dexamethasone on specified days in 28-day treatment cycles for up to 24 courses. The other group receives only oral lenalidomide and dexamethasone on a similar 28-day cycle schedule for the same duration, unless disease progression or unacceptable side effects occur. Throughout the study, participants will undergo regular assessments including blood tests, bone marrow biopsies, imaging scans, and questionnaires to monitor disease status, treatment effects, and quality of life. Follow-up visits will continue every 3 to 12 months for up to 15 years after study treatment ends to track long-term outcomes. Researchers will measure survival, symptom changes, adverse events, and minimal residual disease levels to evaluate treatment impact.
Actively Recruiting
Researchers are evaluating a master screening protocol called Lung-MAP for patients with previously treated non-small cell lung cancer. This phase IIIII trial aims to develop a genomic screening method for large cancer populations and assign participants to appropriate sub-studies based on specific cancer biomarkers. The goal is to compare new targeted therapies designed to block cancer growth or spread with standard care, including sub-studies for patients not eligible for biomarker-driven treatments. The study involves screening patient specimens to determine eligibility for various biomarker-driven or non-matched sub-studies within the Lung-MAP umbrella protocol. This is a screening study without direct interventions instead, patients are assigned to different treatment sub-studies, each operating independently. The protocol also includes an optional ancillary study evaluating attitudes about the return of somatic mutation findings suggestive of germline mutations. Participants provide tumor tissue for biomarker testing, including molecular profiling and PD-L1 analysis, and may submit fresh biopsies and blood samples for circulating tumor DNA testing. Researchers will monitor screening success rates up to three years and collect patient and physician feedback on genetic findings. Participation involves signing informed consent, providing smoking history, and possibly completing surveys. The study duration and assessments vary depending on sub-study assignment and patient progression.
1-10 of 24
1